Use Of GW274150 In The Prophylactic Treatment Of Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

430

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
Migraine Disorders
Interventions
DRUG

GW274150

The tablets used in this study will contain either 5mg or 30mg of GW274150

OTHER

Placebo

Placebo to Match GW274150

Trial Locations (62)

2018

GSK Investigational Site, Antwerp

2317

GSK Investigational Site, Hamar

2408

GSK Investigational Site, Elverum

3000

GSK Investigational Site, Leuven

3400

GSK Investigational Site, Lier

3650

GSK Investigational Site, Oelstykke

4000

GSK Investigational Site, Liège

5000

GSK Investigational Site, Odense C

5007

GSK Investigational Site, Bergen

10117

GSK Investigational Site, Berlin

10435

GSK Investigational Site, Berlin

10961

GSK Investigational Site, Berlin

16132

GSK Investigational Site, Genoa

16153

GSK Investigational Site, Sestri Ponente (GE)

20100

GSK Investigational Site, Turku

24149

GSK Investigational Site, Kiel

27000

GSK Investigational Site, Évreux

28034

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

31300

GSK Investigational Site, Toulouse

32032

GSK Investigational Site, Feltre (BL)

33006

GSK Investigational Site, Oviedo

33210

GSK Investigational Site, Tampere

35625

GSK Investigational Site, Hüttenberg

37100

GSK Investigational Site, Tours

37230

GSK Investigational Site, Luynes

38506

GSK Investigational Site, Voiron

40100

GSK Investigational Site, Jyväskylä

41100

GSK Investigational Site, Modena

42600

GSK Investigational Site, Montbrison

45122

GSK Investigational Site, Essen

46010

GSK Investigational Site, Valencia

48149

GSK Investigational Site, Münster

50100

GSK Investigational Site, Mikkeli

50139

GSK Investigational Site, Florence

59037

GSK Investigational Site, Lille

59410

GSK Investigational Site, Anzin

59690

GSK Investigational Site, Vieux-Condé

65189

GSK Investigational Site, Wiesbaden

69469

GSK Investigational Site, Weinheim

91380

GSK Investigational Site, Chilly-Mazarin

95124

GSK Investigational Site, Catania

DK-2600

GSK Investigational Site, Glostrup Municipality

00100

GSK Investigational Site, Helsinki

00163

GSK Investigational Site, Rome

1261 AN

GSK Investigational Site, Blaricum

5623 EJ

GSK Investigational Site, Eindhoven

4872 LA

GSK Investigational Site, Etten-Leur

4191 AH

GSK Investigational Site, Geldermalsen

5971 BB

GSK Investigational Site, Grubbenvorst

6419 PC

GSK Investigational Site, Heerlen

7555 DL

GSK Investigational Site, Hengelo

1718 BG

GSK Investigational Site, Hoogwoud

6532 SZ

GSK Investigational Site, Nijmegen

3207 NB

GSK Investigational Site, Spijkenisse

5801 CE

GSK Investigational Site, Venray

8011 JW

GSK Investigational Site, Zwolle

N-3515

GSK Investigational Site, Hønefoss

0277

GSK Investigational Site, Oslo

N-1338

GSK Investigational Site, Sandvika

05071

GSK Investigational Site, Ávila

08003

GSK Investigational Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY